Matches in Nanopublications for { ?s ?p ?o <http://rdf.disgenet.org/resource/nanopub/NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance>. }
Showing items 1 to 9 of
9
with 100 items per page.
- source_evidence_literature type ECO_0000212 NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.
- source_evidence_literature label "DisGeNET evidence - LITERATURE" NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.
- source_evidence_literature comment "Gene-disease associations inferred from text-mining the literature." NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.
- NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_assertion description "[Orlistat (Xenicaltrade mark), a US Food and Drug Administration (FDA)-approved drug for bodyweight loss, has recently been demonstrated to exhibit antitumor properties towards prostate cancer cells by virtue of its ability to block the lipogenic activity of fatty acid synthase (FAS).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.
- NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_assertion evidence source_evidence_literature NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.
- NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_assertion SIO_000772 15870086 NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.
- NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_assertion wasDerivedFrom befree-2016 NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.
- NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_assertion wasGeneratedBy ECO_0000203 NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.
- befree-2016 importedOn "2016-02-19" NP493003.RARgHKxtUqcTwDaWQ-CyqnTRUowsUOfcqlpASiFY6IP2U130_provenance.